ݺߣshows by User: PeterPachmann / http://www.slideshare.net/images/logo.gif ݺߣshows by User: PeterPachmann / Tue, 14 May 2019 08:13:10 GMT ݺߣShare feed for ݺߣshows by User: PeterPachmann maintrac how to use worldwide service /slideshow/maintrac-how-to-use-worldwide-service/145461754 190401-maintrac-4-190514081311
How to use the maintrac circulating tumor cells logistics package, how to order maintrac liquid biopsy boxes online, how to order the maintrac courier pickup service.]]>
How to use the maintrac circulating tumor cells logistics package, how to order maintrac liquid biopsy boxes online, how to order the maintrac courier pickup service.]]> Tue, 14 May 2019 08:13:10 GMT /slideshow/maintrac-how-to-use-worldwide-service/145461754 PeterPachmann@slideshare.net(PeterPachmann) maintrac how to use worldwide service PeterPachmann How to use the maintrac circulating tumor cells logistics package, how to order maintrac liquid biopsy boxes online, how to order the maintrac courier pickup service. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-4-190514081311-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> How to use the maintrac circulating tumor cells logistics package, how to order maintrac liquid biopsy boxes online, how to order the maintrac courier pickup service.
maintrac how to use worldwide service from Peter Pachmann
]]> 124 1 https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-4-190514081311-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 maintrac chemo sensitivity on circulating epithelial tumor cells /slideshow/maintrac-chemo-sensitivity-on-circulating-epithelial-tumor-cells/144567181 190401-maintrac-3-190509095856
maintrac liquid biopsy for therapy controll. What to do at increasing cell numbers? Identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product. Chemo Sensitivity Testing: Subdividing and exposing the blood sample to different drugs and concentrations; Determining the rate of dying circulating epithelial tumor cells to identify the most effective drug for the patient.]]>
maintrac liquid biopsy for therapy controll. What to do at increasing cell numbers? Identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product. Chemo Sensitivity Testing: Subdividing and exposing the blood sample to different drugs and concentrations; Determining the rate of dying circulating epithelial tumor cells to identify the most effective drug for the patient.]]> Thu, 09 May 2019 09:58:56 GMT /slideshow/maintrac-chemo-sensitivity-on-circulating-epithelial-tumor-cells/144567181 PeterPachmann@slideshare.net(PeterPachmann) maintrac chemo sensitivity on circulating epithelial tumor cells PeterPachmann maintrac liquid biopsy for therapy controll. What to do at increasing cell numbers? Identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product. Chemo Sensitivity Testing: Subdividing and exposing the blood sample to different drugs and concentrations; Determining the rate of dying circulating epithelial tumor cells to identify the most effective drug for the patient. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190509095856-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> maintrac liquid biopsy for therapy controll. What to do at increasing cell numbers? Identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product. Chemo Sensitivity Testing: Subdividing and exposing the blood sample to different drugs and concentrations; Determining the rate of dying circulating epithelial tumor cells to identify the most effective drug for the patient.
maintrac chemo sensitivity on circulating epithelial tumor cells from Peter Pachmann
]]> 144 2 https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190509095856-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Maintrac Chemo Sensitivity Testing of Circualting Tumor Cells /slideshow/maintrac-chemo-sensitivity-testing-of-circualting-tumor-cells/143197865 190401-maintrac-3-190502102332
Increasing cell numbers by 10fold should lead to subdividing and exposing the blood sample to different drugs and concentrations and determining the rate of dying circulating epithelial tumor cells to identify the most effective cancer drug for the patient.]]>
Increasing cell numbers by 10fold should lead to subdividing and exposing the blood sample to different drugs and concentrations and determining the rate of dying circulating epithelial tumor cells to identify the most effective cancer drug for the patient.]]> Thu, 02 May 2019 10:23:32 GMT /slideshow/maintrac-chemo-sensitivity-testing-of-circualting-tumor-cells/143197865 PeterPachmann@slideshare.net(PeterPachmann) Maintrac Chemo Sensitivity Testing of Circualting Tumor Cells PeterPachmann Increasing cell numbers by 10fold should lead to subdividing and exposing the blood sample to different drugs and concentrations and determining the rate of dying circulating epithelial tumor cells to identify the most effective cancer drug for the patient. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190502102332-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Increasing cell numbers by 10fold should lead to subdividing and exposing the blood sample to different drugs and concentrations and determining the rate of dying circulating epithelial tumor cells to identify the most effective cancer drug for the patient.
Maintrac Chemo Sensitivity Testing of Circualting Tumor Cells from Peter Pachmann
]]> 53 2 https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190502102332-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 maintrac liquid biopsy on circulating epithelial tumor cells /PeterPachmann/maintrac-liquid-biopsy-on-circulating-epithelial-tumor-cells 190401-maintrac-2-190501135845
maintrac liquid biopsy on circulating epithelial tumor cells. Microscope based semi-automated discrimination of cancer cells, effectiveness testing of cancer drugs (before treatment) andtherapy monitoring ]]>
maintrac liquid biopsy on circulating epithelial tumor cells. Microscope based semi-automated discrimination of cancer cells, effectiveness testing of cancer drugs (before treatment) andtherapy monitoring ]]> Wed, 01 May 2019 13:58:45 GMT /PeterPachmann/maintrac-liquid-biopsy-on-circulating-epithelial-tumor-cells PeterPachmann@slideshare.net(PeterPachmann) maintrac liquid biopsy on circulating epithelial tumor cells PeterPachmann maintrac liquid biopsy on circulating epithelial tumor cells. Microscope based semi-automated discrimination of cancer cells, effectiveness testing of cancer drugs (before treatment) and�therapy monitoring <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-2-190501135845-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> maintrac liquid biopsy on circulating epithelial tumor cells. Microscope based semi-automated discrimination of cancer cells, effectiveness testing of cancer drugs (before treatment) and�therapy monitoring
maintrac liquid biopsy on circulating epithelial tumor cells from Peter Pachmann
]]> 91 5 https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-2-190501135845-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 150903 maintrac-hormonal-therapy https://de.slideshare.net/PeterPachmann/150903-maintrachormonaltherapy 150903-maintrac-hormonal-therapy-150909082405-lva1-app6891
maintrac® circulating tumor cells as a decision aid in hormonal therapy for patients with breast cancer.]]>
maintrac® circulating tumor cells as a decision aid in hormonal therapy for patients with breast cancer.]]> Wed, 09 Sep 2015 08:24:04 GMT https://de.slideshare.net/PeterPachmann/150903-maintrachormonaltherapy PeterPachmann@slideshare.net(PeterPachmann) 150903 maintrac-hormonal-therapy PeterPachmann maintrac® circulating tumor cells as a decision aid in hormonal therapy for patients with breast cancer. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/150903-maintrac-hormonal-therapy-150909082405-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> maintrac® circulating tumor cells as a decision aid in hormonal therapy for patients with breast cancer.
from Peter Pachmann
]]> 731 10 https://cdn.slidesharecdn.com/ss_thumbnails/150903-maintrac-hormonal-therapy-150909082405-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 ASCO 2015 Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma /slideshow/asco-2015-vemurafenib-to-eliminate-brafmutated-circulating-melanoma-tumor-cells-from-blood-of-patients-with-malignant-melanomacompressed/49724336 asco2015-vemurafenibtoeliminatebraf-mutatedcirculatingmelanomatumorcellsfrombloodofpatientswithmalig-150623085535-lva1-app6891
ASCO 2015: Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma]]>
ASCO 2015: Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma]]> Tue, 23 Jun 2015 08:55:35 GMT /slideshow/asco-2015-vemurafenib-to-eliminate-brafmutated-circulating-melanoma-tumor-cells-from-blood-of-patients-with-malignant-melanomacompressed/49724336 PeterPachmann@slideshare.net(PeterPachmann) ASCO 2015 Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma PeterPachmann ASCO 2015: Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/asco2015-vemurafenibtoeliminatebraf-mutatedcirculatingmelanomatumorcellsfrombloodofpatientswithmalig-150623085535-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> ASCO 2015: Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma
ASCO 2015 Vemurafenib to eliminate braf-mutated circulating melanoma tumor cells from blood of patients with malignant melanoma from Peter Pachmann
]]> 1000 3 https://cdn.slidesharecdn.com/ss_thumbnails/asco2015-vemurafenibtoeliminatebraf-mutatedcirculatingmelanomatumorcellsfrombloodofpatientswithmalig-150623085535-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Staining of Circulating Tumor Cells - as easy as a blood picture /slideshow/150316-maintracctcstaining/46139913 150316-maintrac-ctc-staining-150322115130-conversion-gate01
Staining of Circulating Tumor Cells - as easy as a blood picture. Staining is moch more sensitive than isolation of CTCs.]]>
Staining of Circulating Tumor Cells - as easy as a blood picture. Staining is moch more sensitive than isolation of CTCs.]]> Sun, 22 Mar 2015 11:51:29 GMT /slideshow/150316-maintracctcstaining/46139913 PeterPachmann@slideshare.net(PeterPachmann) Staining of Circulating Tumor Cells - as easy as a blood picture PeterPachmann Staining of Circulating Tumor Cells - as easy as a blood picture. Staining is moch more sensitive than isolation of CTCs. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/150316-maintrac-ctc-staining-150322115130-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Staining of Circulating Tumor Cells - as easy as a blood picture. Staining is moch more sensitive than isolation of CTCs.
Staining of Circulating Tumor Cells - as easy as a blood picture from Peter Pachmann
]]> 2542 3 https://cdn.slidesharecdn.com/ss_thumbnails/150316-maintrac-ctc-staining-150322115130-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 CTC Methods in comparison /slideshow/ctc-methods-in-comparison/42987403 ctc-comparison-141224061434-conversion-gate01
A small presentation on CTC Methods in comparison to each other.]]>
A small presentation on CTC Methods in comparison to each other.]]> Wed, 24 Dec 2014 06:14:34 GMT /slideshow/ctc-methods-in-comparison/42987403 PeterPachmann@slideshare.net(PeterPachmann) CTC Methods in comparison PeterPachmann A small presentation on CTC Methods in comparison to each other. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ctc-comparison-141224061434-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A small presentation on CTC Methods in comparison to each other.
CTC Methods in comparison from Peter Pachmann
]]> 1306 2 https://cdn.slidesharecdn.com/ss_thumbnails/ctc-comparison-141224061434-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Chemosensitivity on circulating tumor spheres /slideshow/chemosensitivity-on-circulating-tumor-spheres-42132420/42132420 chemosensitivityoncirculatingtumorspheres-141128085328-conversion-gate02
Chemosensitivity on circulating tumor spheres based on the maintrac circulating tumor cell detection method.]]>
Chemosensitivity on circulating tumor spheres based on the maintrac circulating tumor cell detection method.]]> Fri, 28 Nov 2014 08:53:28 GMT /slideshow/chemosensitivity-on-circulating-tumor-spheres-42132420/42132420 PeterPachmann@slideshare.net(PeterPachmann) Chemosensitivity on circulating tumor spheres PeterPachmann Chemosensitivity on circulating tumor spheres based on the maintrac circulating tumor cell detection method. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/chemosensitivityoncirculatingtumorspheres-141128085328-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Chemosensitivity on circulating tumor spheres based on the maintrac circulating tumor cell detection method.
Chemosensitivity on circulating tumor spheres from Peter Pachmann
]]> 840 5 https://cdn.slidesharecdn.com/ss_thumbnails/chemosensitivityoncirculatingtumorspheres-141128085328-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome /slideshow/chemosensitivity-jct-2013-35272883/35272883 chemosensitivityjct2013-140529130611-phpapp01
ABSTRACT Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empiri- cally developed recommendations derived from statistical relapse rates occurring years after the treatment in the adju- vant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitiv- ity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percent- ages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.]]>
ABSTRACT Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empiri- cally developed recommendations derived from statistical relapse rates occurring years after the treatment in the adju- vant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitiv- ity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percent- ages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.]]> Thu, 29 May 2014 13:06:11 GMT /slideshow/chemosensitivity-jct-2013-35272883/35272883 PeterPachmann@slideshare.net(PeterPachmann) Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome PeterPachmann ABSTRACT Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empiri- cally developed recommendations derived from statistical relapse rates occurring years after the treatment in the adju- vant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitiv- ity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percent- ages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/chemosensitivityjct2013-140529130611-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> ABSTRACT Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empiri- cally developed recommendations derived from statistical relapse rates occurring years after the treatment in the adju- vant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitiv- ity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percent- ages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.
Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome from Peter Pachmann
]]> 1463 6 https://cdn.slidesharecdn.com/ss_thumbnails/chemosensitivityjct2013-140529130611-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Assessing the efficacy of targeted therapy using circulating epithelial tumor cells clin oncol_2011 /PeterPachmann/assessing-the-efficacy-of-targeted-therapy-using-circulating-epithelial-tumor-cells-clin-oncol2011 assessingtheefficacyoftargetedtherapyusingcirculatingepithelialtumorcellsclinoncol2011-140522022812-phpapp02
Abstract Purpose In malignant tumors, predictive markers have been developed with respect to targeted therapies. One of the Wrst targeted therapies was the hormone-blocking treatment of tumors of the male and female reproductive system. A typical therapy in breast cancer is the use of the selective estrogen receptor modulator, tamoxifen. However, only some of the patients, positive for the target molecules, respond to the selected therapy. It would, therefore, be highly desirable to have a tool to promptly assess the therapeutic eYcacy of the applied agent in the individual patient. Methods Longitudinal observation of CETC provides a unique tool for monitoring therapy response. About 178 patients with breast cancer were followed prospectively during hormone therapy, requiring only 1 ml of peripheral blood, using a Xuorochrome-labeled antibody against surface- epithelial antigen. Image analysis allowed CETC numbers to be calculated in relation to blood volume and monitoring over the entire course of treatment. Results A more than tenfold increase in CETC during therapy was a strong indicator of looming relapse (P = 0.0001 hazard ratio 5.5; 95% conWdence interval 1,297–23,626), and a Cox regression analysis of age, tumor size, receptor expression, nodal status and previous treatment resulted in a regression model, in which CETC behavior was the parameter with the highest independent correlation to relapse-free survival. Conclusions The change in the number of CETC (increase or decrease) may, in the future, be used to guide therapy in order to change to other available treatment options in good time. ]]>
Abstract Purpose In malignant tumors, predictive markers have been developed with respect to targeted therapies. One of the Wrst targeted therapies was the hormone-blocking treatment of tumors of the male and female reproductive system. A typical therapy in breast cancer is the use of the selective estrogen receptor modulator, tamoxifen. However, only some of the patients, positive for the target molecules, respond to the selected therapy. It would, therefore, be highly desirable to have a tool to promptly assess the therapeutic eYcacy of the applied agent in the individual patient. Methods Longitudinal observation of CETC provides a unique tool for monitoring therapy response. About 178 patients with breast cancer were followed prospectively during hormone therapy, requiring only 1 ml of peripheral blood, using a Xuorochrome-labeled antibody against surface- epithelial antigen. Image analysis allowed CETC numbers to be calculated in relation to blood volume and monitoring over the entire course of treatment. Results A more than tenfold increase in CETC during therapy was a strong indicator of looming relapse (P = 0.0001 hazard ratio 5.5; 95% conWdence interval 1,297–23,626), and a Cox regression analysis of age, tumor size, receptor expression, nodal status and previous treatment resulted in a regression model, in which CETC behavior was the parameter with the highest independent correlation to relapse-free survival. Conclusions The change in the number of CETC (increase or decrease) may, in the future, be used to guide therapy in order to change to other available treatment options in good time. ]]> Thu, 22 May 2014 02:28:12 GMT /PeterPachmann/assessing-the-efficacy-of-targeted-therapy-using-circulating-epithelial-tumor-cells-clin-oncol2011 PeterPachmann@slideshare.net(PeterPachmann) Assessing the efficacy of targeted therapy using circulating epithelial tumor cells clin oncol_2011 PeterPachmann Abstract Purpose In malignant tumors, predictive markers have been developed with respect to targeted therapies. One of the Wrst targeted therapies was the hormone-blocking treatment of tumors of the male and female reproductive system. A typical therapy in breast cancer is the use of the selective estrogen receptor modulator, tamoxifen. However, only some of the patients, positive for the target molecules, respond to the selected therapy. It would, therefore, be highly desirable to have a tool to promptly assess the therapeutic eYcacy of the applied agent in the individual patient. Methods Longitudinal observation of CETC provides a unique tool for monitoring therapy response. About 178 patients with breast cancer were followed prospectively during hormone therapy, requiring only 1 ml of peripheral blood, using a Xuorochrome-labeled antibody against surface- epithelial antigen. Image analysis allowed CETC numbers to be calculated in relation to blood volume and monitoring over the entire course of treatment. Results A more than tenfold increase in CETC during therapy was a strong indicator of looming relapse (P = 0.0001 hazard ratio 5.5; 95% conWdence interval 1,297–23,626), and a Cox regression analysis of age, tumor size, receptor expression, nodal status and previous treatment resulted in a regression model, in which CETC behavior was the parameter with the highest independent correlation to relapse-free survival. Conclusions The change in the number of CETC (increase or decrease) may, in the future, be used to guide therapy in order to change to other available treatment options in good time. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/assessingtheefficacyoftargetedtherapyusingcirculatingepithelialtumorcellsclinoncol2011-140522022812-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Abstract Purpose In malignant tumors, predictive markers have been developed with respect to targeted therapies. One of the Wrst targeted therapies was the hormone-blocking treatment of tumors of the male and female reproductive system. A typical therapy in breast cancer is the use of the selective estrogen receptor modulator, tamoxifen. However, only some of the patients, positive for the target molecules, respond to the selected therapy. It would, therefore, be highly desirable to have a tool to promptly assess the therapeutic eYcacy of the applied agent in the individual patient. Methods Longitudinal observation of CETC provides a unique tool for monitoring therapy response. About 178 patients with breast cancer were followed prospectively during hormone therapy, requiring only 1 ml of peripheral blood, using a Xuorochrome-labeled antibody against surface- epithelial antigen. Image analysis allowed CETC numbers to be calculated in relation to blood volume and monitoring over the entire course of treatment. Results A more than tenfold increase in CETC during therapy was a strong indicator of looming relapse (P = 0.0001 hazard ratio 5.5; 95% conWdence interval 1,297–23,626), and a Cox regression analysis of age, tumor size, receptor expression, nodal status and previous treatment resulted in a regression model, in which CETC behavior was the parameter with the highest independent correlation to relapse-free survival. Conclusions The change in the number of CETC (increase or decrease) may, in the future, be used to guide therapy in order to change to other available treatment options in good time.
Assessing the efficacy of targeted therapy using circulating epithelial tumor cells clin oncol_2011 from Peter Pachmann
]]> 499 3 https://cdn.slidesharecdn.com/ss_thumbnails/assessingtheefficacyoftargetedtherapyusingcirculatingepithelialtumorcellsclinoncol2011-140522022812-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-PeterPachmann-48x48.jpg?cb=1559824087 Peter Pachmann started his professional career while studying communicaton design in Hamburg 1999, working at E+H Systemhaus GmbH, a local advertising agency as an Art Director. Later in 1999, he founded his own advertising agency PADICON and specialized quickly on Direct Marketing. In 2003, Peter Pachmann as CEO was responsible for a contract, making the agency an official “Partner of Deutsche Post AG”, Direct Marketing section of Schleswig-Holstein and Hamburg. Due to the great success, PADICON took over the adverb advertising agency GmbH in 2005. Peter Pachmann as Managing Director and Art Director was mainly responsible for complex communication concepts for customers across divers... http://www.maintrac.de https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-4-190514081311-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/maintrac-how-to-use-worldwide-service/145461754 maintrac how to use wo... https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190509095856-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/maintrac-chemo-sensitivity-on-circulating-epithelial-tumor-cells/144567181 maintrac chemo sensiti... https://cdn.slidesharecdn.com/ss_thumbnails/190401-maintrac-3-190502102332-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/maintrac-chemo-sensitivity-testing-of-circualting-tumor-cells/143197865 Maintrac Chemo Sensiti...